期刊文献+

CAG方案治疗骨髓增生异常综合征疗效观察 被引量:4

原文传递
导出
摘要 目的观察CAG方案治疗骨髓增生异常综合征(MDS)疗效。方法患者接受CAG方案化疗,用此方案1个疗程未达缓解,则再用第2疗程,仍未达缓解者改用其他方法治疗缓解后,采用CAG方案与常规化疗交替。结果20例患者中,完全缓解(CR)9例,部分缓解(PR)6例,未缓解(NR)5例,有效(CR+PR)率为75.0%,CR率为45.0%;8例进展为急性髓系白血病(AML),中位时间为11.5个月(6—16个月);中位死亡时间16.5个月(10~22个月),1年总生存率78.3%,2年总生存率61.5%,病态造血明显好转。结论CAG方案治疗MDS安全有效,可延长生存期,改善生活质量,但是长期疗效仍需进一步观察。
出处 《白血病.淋巴瘤》 CAS 2010年第10期630-631,共2页 Journal of Leukemia & Lymphoma
  • 相关文献

参考文献6

  • 1Bai A,Kojima H,Hori M,et al.Priming with G-CSF effectively enhances low-dose Aar-C-induced in vivo apoptosis in myeloid leukemia cells.Exp Hematol,1999,27:259-265.
  • 2ChesonBD,BennettJM,KopeckyKJ,周学慧,肖志坚.国际工作组关于急性髓系白血病治疗试验的诊断、疗效标准的标准化、治疗结局和报告标准的修订建议[J].白血病.淋巴瘤,2004,13(4):246-250. 被引量:31
  • 3郑美芳,陈秋生,陈钰.CAG预激方案治疗骨髓增生异常综合征RAEB-T的疗效观察[J].白血病.淋巴瘤,2006,15(2):133-134. 被引量:8
  • 4Katagiri T,Mpyazawas K,Mishimaki J,et al.Combination of G-CSF and low-dose arabinaside further enhances myeloid differentiation in leukemia cells in vitro.Leuk Lymphoma,2000.39:173-184.
  • 5Akashi G,Kuriyama T,Tawara M,et al.Trial of combined aclarubicin with G-CSF therapy or refractory acute meloid leukemia.Blood,2004,83:2086-2092.
  • 6Saito K,Nakamura Y,Aoyagi M,et al.Low-dose cytarabine and aclarubrcin in combination with granulocyte colony-stimulating factor (CAG regimen)for previously treated patients with replased or primary resistant acute myelogenous leukemia (AML) and refractory anemia with excess blast in transformation.Int J Hematol,2000,17:238-244.

二级参考文献3

  • 1Harouseau J L,Wu D P.The use of GM-CSF and G-CSF in the treatment of acute leukemia[J].Leuk Lymph,1995,18(2):405-412.
  • 2Bai A,Kojima H,Hori M,et al.Priming with G-CSF effectively enhances low-dose.Ara-C-induced in vivo apoptosis in myeloid leukemia cells[J].Exp Hematol,1999,27(2):259-265.
  • 3Katagiri T,Miyazawa K,Nishimaki J,et al.Combination of granulocyte colony-stmulating factor and low-close cytosine arabinoside further enhances myeloid differentiation in leukemia cells in vitro [J].Leuk Lymphoma,2000,39(1-2):173-184.

共引文献37

同被引文献48

  • 1苏贵平,汪兴洪,黄东平,戴艳,姚军萍.预激方案治疗老年和难治性急性髓系白血病疗效观察[J].白血病.淋巴瘤,2007,16(1):57-58. 被引量:5
  • 2Nimer SD. Myelodysplastic syndromes [ J ]. Blood, 2008 ; 11:4841 - 4851.
  • 3Nolte F, Hofmann W K, Molecular mechanisms involved in the progression of myelodysplastic syndromes [ J ]. Future Oncol, 2010 ; 6 : 445 - 455.
  • 4Greenberg P, Cox C, LeBeau MM, et al. Inter- national scoring system for evaluating prognosisin myebdysplastic syndromes. Blood. 1997 ; 89 (6) : 2079 - 2088.
  • 5NCCN Practice Guidelines in Oneology. Myelo- dysplastic syndromes, v. 2. 2010.
  • 6Kook H, Zeng W, Guibin C, et al. Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia Exp Hema- tol, 2001 ;29 ( 11 ) : 1270 - 1277.
  • 7Sloand EM, Rezvani K. The role of the immune system in myelodysplasia: implications for thera- py. Semin Hematol 2008 ;45 ( 1 ) : 39 -48.
  • 8Broliden PA, Dahl IM, Hast R, et al. Antithy- mocyte globulin and Cyclosporine A as combina- tion therapy for low - risk nonsideroblastic myel- odysplastic syndromes. Haematologica,2006 ;91 (5) :583 -584.
  • 9Folkman J. Tumor angiogenesis: therapeutic im- plication[J]. N Engl J Med, 1971;285:1182 - 1186.
  • 10Didier B, Laurence L, Micheline T, et al. A non - randomised dose - escalating phase 11 study of thalidomide for the treatment of patients with low -risk myelodysplastic syndromes: the Thai- SMD -2000 trial of the Groupe Franc? ais des Myelodysplasies [ J]. British Journal of Haematology, 2005 ; 131 : 609 - 618.

引证文献4

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部